Last reviewed · How we verify
A: OLP-1002
At a glance
| Generic name | A: OLP-1002 |
|---|---|
| Also known as | OLP-1002: A |
| Sponsor | OliPass Australia Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint (PHASE2)
- OLP-1002 is Being Studied in the Treatment of Pain. (EARLY_PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A: OLP-1002 CI brief — competitive landscape report
- A: OLP-1002 updates RSS · CI watch RSS
- OliPass Australia Pty Ltd portfolio CI